thalidomide has been researched along with Edema in 24 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Edema: Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination." | 9.12 | A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 7.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| " In this study we examined the effect of drugs interfering with TNF expression (thalidomide) and activity (infliximab) and compared it to that of a H(1)R histamine receptor antagonist (loratadine) in a model of histamine-induced rat hind-paw oedema formation." | 7.75 | Evidence for the contribution of tumour necrosis factor in oedema formation induced by histamine in the hind paw of the rat. ( Goulas, A; Kalokasidis, K; Kokkas, B; Mirtsou, V; Molyva, D, 2009) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 7.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "In an open study, 17 patients (16 women, 1 man) with refractory or severe rheumatoid arthritis were treated with thalidomide." | 7.67 | Treatment of refractory rheumatoid arthritis--the thalidomide experience. ( Gutiérrez-Montes, O; Gutiérrez-Rodríguez, O; Starusta-Bacal, P, 1989) |
| "Thalidomide is an anti-neoplastic agent with anti-angiogenic and other mechanisms of action." | 5.34 | Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. ( Chan, P; Cheung, TT; Chok, SH; Epstein, RJ; Fan, ST; Lam, V; Ng, KK; Poon, RT; Wong, H; Yau, T, 2007) |
| "Thalidomide has been shown to selectively inhibit TNF-alpha production." | 5.31 | Analgesic effect of thalidomide on inflammatory pain. ( Cunha, FQ; Ferreira, SH; Ribeiro, RA; Vale, ML, 2000) |
| "This phase II study evaluated the combination of semaxanib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor-2, and thalidomide in patients with metastatic melanoma to assess the efficacy, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the combination." | 5.12 | A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ( Beeram, M; Berg, K; de Bono, JS; Eckhart, SG; Forero, L; Hammond, LA; Izbicka, E; Mita, AC; Mita, MM; Patnaik, A; Rowinsky, EK; Simmons, P; Takimoto, C; Tolcher, AW; Weiss, GR, 2007) |
| " We report the final results of a phase II trial of thalidomide as initial therapy for early-stage multiple myeloma in an attempt to delay progression to symptomatic disease." | 5.10 | Thalidomide as initial therapy for early-stage myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Iturria, N; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 3.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| " In this study we examined the effect of drugs interfering with TNF expression (thalidomide) and activity (infliximab) and compared it to that of a H(1)R histamine receptor antagonist (loratadine) in a model of histamine-induced rat hind-paw oedema formation." | 3.75 | Evidence for the contribution of tumour necrosis factor in oedema formation induced by histamine in the hind paw of the rat. ( Goulas, A; Kalokasidis, K; Kokkas, B; Mirtsou, V; Molyva, D, 2009) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 3.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "In an open study, 17 patients (16 women, 1 man) with refractory or severe rheumatoid arthritis were treated with thalidomide." | 3.67 | Treatment of refractory rheumatoid arthritis--the thalidomide experience. ( Gutiérrez-Montes, O; Gutiérrez-Rodríguez, O; Starusta-Bacal, P, 1989) |
| "On rat paw edema and hyperalgesia assays, compound 9, (1,4-phthalazinedione) demonstrated the highest in vivo anti-inflammatory activity." | 1.43 | Thalidomide analogues: Tumor necrosis factor-alpha inhibitors and their evaluation as anti-inflammatory agents. ( Bollini, M; Bruno, AM; Casal, JJ; Lombardo, ME, 2016) |
| "Echocardiography detected left ventricular hypertrophy and diastolic dysfunction." | 1.39 | Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome. ( Hisa, S; Kanno, Y; Kobayashi, A; Mizukami, H; Nakazato, K; Noji, H; Ogawa, K; Ohkawara, H; Saitoh, S; Shichishima-Nakamura, A; Suzuki, H; Takahashi, H; Takeishi, Y; Yokokawa, T; Yoshihisa, A, 2013) |
| "Rats treated with thalidomide showed significant increase in SC water compared with naive rats, but not vehicle-treated rats; their neutrophil infiltration and amount of spared/destroyed cord tissue was not different from vehicle-treated rats; and in no case was motor performance improved after thalidomide." | 1.35 | Thalidomide fails to be therapeutic following contusive spinal cord injury in rats. ( Franco-Bourland, RE; Fuchs, B; Grijalva, I; Guízar-Sahagún, G; Madrazo, I; Martínez-Cruz, A; Reyes-Alva, HJ, 2009) |
| "Thalidomide is an anti-neoplastic agent with anti-angiogenic and other mechanisms of action." | 1.34 | Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. ( Chan, P; Cheung, TT; Chok, SH; Epstein, RJ; Fan, ST; Lam, V; Ng, KK; Poon, RT; Wong, H; Yau, T, 2007) |
| "Oral mucositis is a frequent side-effect of cancer therapy." | 1.33 | Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. ( Augusto, RF; Brito, GA; Cunha, FQ; Falcão, BA; Leitão, BT; Lima, V; Rebouças, CG; Ribeiro, RA; Souza, ML, 2005) |
| " Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes." | 1.32 | Reactions and their management. ( Ganapati, R; Pai, VV, 2004) |
| "Thalidomide has been shown to selectively inhibit TNF-alpha production." | 1.31 | Analgesic effect of thalidomide on inflammatory pain. ( Cunha, FQ; Ferreira, SH; Ribeiro, RA; Vale, ML, 2000) |
| " In the present study, we investigated the oedematogenic activity of both toxins, characterizing the time-course and dose-response of this pro-inflammatory event." | 1.31 | The effect of tumour necrosis factor (TNF) inhibitors in Clostridium difficile toxin-induced paw oedema and neutrophil migration. ( Carneiro-Filho, BA; Lima, AA; Ribeiro, RA; Souza, ML, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 14 (58.33) | 29.6817 |
| 2010's | 6 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| da Silva, YK | 1 |
| Augusto, CV | 1 |
| de Castro Barbosa, ML | 1 |
| de Albuquerque Melo, GM | 1 |
| de Queiroz, AC | 1 |
| de Lima Matos Freire Dias, T | 1 |
| Júnior, WB | 1 |
| Barreiro, EJ | 1 |
| Lima, LM | 2 |
| Alexandre-Moreira, MS | 2 |
| Yokokawa, T | 1 |
| Nakazato, K | 1 |
| Kanno, Y | 1 |
| Mizukami, H | 1 |
| Kobayashi, A | 1 |
| Yoshihisa, A | 1 |
| Takahashi, H | 1 |
| Shichishima-Nakamura, A | 1 |
| Ohkawara, H | 1 |
| Noji, H | 1 |
| Suzuki, H | 1 |
| Saitoh, S | 1 |
| Ogawa, K | 1 |
| Hisa, S | 1 |
| Takeishi, Y | 1 |
| Hobeika, L | 1 |
| Self, SE | 1 |
| Velez, JC | 1 |
| Casal, JJ | 1 |
| Bollini, M | 1 |
| Lombardo, ME | 1 |
| Bruno, AM | 1 |
| De Lazzari, M | 1 |
| Fedrigo, M | 1 |
| Migliore, F | 1 |
| Cianci, A | 1 |
| Cacciavillani, L | 1 |
| Tarantini, G | 1 |
| Giorgi, B | 1 |
| Iliceto, S | 1 |
| Thiene, G | 1 |
| Valente, M | 1 |
| Angelini, A | 1 |
| Adami, F | 1 |
| Perazzolo Marra, M | 1 |
| Kalokasidis, K | 1 |
| Molyva, D | 1 |
| Mirtsou, V | 1 |
| Kokkas, B | 1 |
| Goulas, A | 1 |
| Reyes-Alva, HJ | 1 |
| Franco-Bourland, RE | 1 |
| Martínez-Cruz, A | 1 |
| Grijalva, I | 1 |
| Fuchs, B | 1 |
| Madrazo, I | 1 |
| Guízar-Sahagún, G | 1 |
| dos Santos, JL | 1 |
| Lanaro, C | 1 |
| Gambero, S | 1 |
| Franco-Penteado, CF | 1 |
| Wade, M | 1 |
| Yerigenahally, S | 1 |
| Kutlar, A | 1 |
| Meiler, SE | 1 |
| Costa, FF | 1 |
| Chung, M | 1 |
| Viana, CF | 1 |
| Melo, DH | 1 |
| Carneiro-Filho, BA | 2 |
| Michelin, MA | 1 |
| Brito, GA | 2 |
| Cunha, FQ | 3 |
| Lima, AA | 2 |
| Ribeiro, RA | 4 |
| Rajkumar, SV | 2 |
| Gertz, MA | 2 |
| Lacy, MQ | 3 |
| Dispenzieri, A | 2 |
| Fonseca, R | 2 |
| Geyer, SM | 1 |
| Iturria, N | 1 |
| Kumar, S | 1 |
| Lust, JA | 2 |
| Kyle, RA | 2 |
| Greipp, PR | 2 |
| Witzig, TE | 3 |
| Rechner, I | 1 |
| Brito-Babapulle, F | 1 |
| Fielden, J | 1 |
| SKRE, H | 1 |
| Ganapati, R | 1 |
| Pai, VV | 1 |
| Lima, V | 1 |
| Rebouças, CG | 1 |
| Falcão, BA | 1 |
| Augusto, RF | 1 |
| Souza, ML | 2 |
| Leitão, BT | 1 |
| Rocha, AC | 1 |
| Fernandes, ES | 1 |
| Passos, GF | 1 |
| Calixto, JB | 1 |
| Campos, MM | 1 |
| Dingli, D | 1 |
| Nowakowski, GS | 1 |
| Hayman, S | 1 |
| Mita, MM | 1 |
| Rowinsky, EK | 1 |
| Forero, L | 1 |
| Eckhart, SG | 1 |
| Izbicka, E | 1 |
| Weiss, GR | 1 |
| Beeram, M | 1 |
| Mita, AC | 1 |
| de Bono, JS | 1 |
| Tolcher, AW | 1 |
| Hammond, LA | 1 |
| Simmons, P | 1 |
| Berg, K | 1 |
| Takimoto, C | 1 |
| Patnaik, A | 1 |
| Hoyer, RJ | 1 |
| Leung, N | 1 |
| Yau, T | 1 |
| Chan, P | 1 |
| Wong, H | 1 |
| Ng, KK | 1 |
| Chok, SH | 1 |
| Cheung, TT | 1 |
| Lam, V | 1 |
| Epstein, RJ | 1 |
| Fan, ST | 1 |
| Poon, RT | 1 |
| Oliver, SJ | 1 |
| Freeman, SL | 1 |
| Corral, LG | 1 |
| Ocampo, CJ | 1 |
| Kaplan, G | 1 |
| Vale, ML | 1 |
| Ferreira, SH | 1 |
| Gutiérrez-Rodríguez, O | 1 |
| Starusta-Bacal, P | 1 |
| Gutiérrez-Montes, O | 1 |
| Jonsson, BG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thalidomide and Edema
| Article | Year |
|---|---|
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Asthenia; Dose-Response Relationship, Drug; | 2007 |
22 other studies available for thalidomide and Edema
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Ear; Edema; Female; Freund's Adjuvant; Hyd | 2010 |
Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome.
Topics: Aged; Dexamethasone; Diuretics; Drug Resistance; Edema; Furosemide; Heart Failure; Humans; Hypertens | 2013 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Thalidomide analogues: Tumor necrosis factor-alpha inhibitors and their evaluation as anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Carrageenan; Edema; Foot; Hyperalge | 2016 |
Nonamyloidotic Light Chain Cardiomyopathy: The Arrhythmogenic Magnetic Resonance Pattern.
Topics: Bortezomib; Cardiomyopathies; Combined Modality Therapy; Defibrillators, Implantable; Dexamethasone; | 2016 |
Evidence for the contribution of tumour necrosis factor in oedema formation induced by histamine in the hind paw of the rat.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Edema; | 2009 |
Thalidomide fails to be therapeutic following contusive spinal cord injury in rats.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Fema | 2009 |
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms.
Topics: Acetic Acid; Analgesics; Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Antisickling Agents | 2011 |
Pro-inflammatory effects of cholera toxin: role of tumor necrosis factor alpha.
Topics: Animals; Cell Movement; Cholera Toxin; Dexamethasone; Disease Models, Animal; Dose-Response Relation | 2002 |
Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Combined Modality Th | 2003 |
[THALIDOMIDE POLYNEURITIS: A FORM OF RIBOFLAVIN AVITAMINOSIS?].
Topics: Avitaminosis; Dermatology; Drug Hypersensitivity; Edema; Folic Acid; Geriatrics; Headache; Neuritis; | 1963 |
Reactions and their management.
Topics: Arthritis; Cicatrix; Clofazimine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Ad | 2004 |
Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Cricetinae; Disease Models, Animal; Edema; Erythe | 2005 |
Assessment of TNFalpha contribution to the functional up-regulation of kinin B(1) receptors in the mouse paw after treatment with LPS.
Topics: Animals; Bradykinin; Edema; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Mice, | 2005 |
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Clinical Trials, Phase | 2005 |
Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis.
Topics: Amyloidosis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Captopril; Ches | 2007 |
Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Ankle; Carcinoma, Hepatocellular; Edema; Fe | 2007 |
Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis.
Topics: Animals; Arthritis, Experimental; Edema; Extremities; Female; Interleukin-2; Leukocytes; Lymphocyte | 1999 |
Analgesic effect of thalidomide on inflammatory pain.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Carrageenan; Edema | 2000 |
The effect of tumour necrosis factor (TNF) inhibitors in Clostridium difficile toxin-induced paw oedema and neutrophil migration.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Botulinum Toxins; Botulinum Toxins, Type A; Chemot | 2001 |
Treatment of refractory rheumatoid arthritis--the thalidomide experience.
Topics: Adult; Aged; Arthritis, Rheumatoid; Edema; Female; Humans; Male; Middle Aged; Pain; Sleep Stages; Th | 1989 |
Effects of thalidomide on the embryonic development of the axolotl (Ambystoma mexicanum).
Topics: Abnormalities, Drug-Induced; Ambystoma; Animals; Cell Differentiation; Cell Division; Edema; Heart R | 1972 |